Friday, 16 October 2026European Markets

TEKNA HOLDING Stock Over 10% Down So Far Today

Loading stream...

(VIANEWS) - Shares of TEKNA HOLDING (Oslo Børs Benchmark Index_GI: TEKNA.OL) slid by a staggering 10.26% to kr6.82 at 11:37 EST on Friday, after two successive sessions in a row of gains. Oslo Børs Benchmark Index_GI is jumping 0.6% to kr1,242.80, after two sequential sessions in a row of losses. This seems, so far, a somewhat bullish trend trading session today.

TEKNA HOLDING's last close was kr7.60, 62% under its 52-week high of kr20.00.

About TEKNA HOLDING

Tekna Holding ASA develops, manufactures, and sells micro and nano powders, and plasma process solutions in North America, Europe, Asia, and internationally. The company offers spherical powders, such as titanium, nickel, and aluminum alloys, as well as tungsten and tantalum; and nanopowders, including nickel nanopowder, silicon nanopowder, copper nanopowder, and boron nitride nanotubes for use in additive manufacturing, metal injection molding, thermal spray, and hot isostatic pressing. It serves aviation, aerospace, medical, mining and drilling, energy storage, and microelectronics industries. The company was founded in 1990 and is headquartered in Sherbrooke, Canada. Tekna Holding ASA is a subsidiary of Arendals Fossekompani ASA.

Earnings Per Share

As for profitability, TEKNA HOLDING has a trailing twelve months EPS of kr-1.23.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -32.23%.

Volume

Today's last reported volume for TEKNA HOLDING is 11872 which is 84.1% below its average volume of 74683.

More news about TEKNA HOLDING (TEKNA.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com